				Page 1 of 1/3
ſ	FORM PTO 1449	ATTY. DOCKET NO. 0207-0004	APPLICATION NO. 09/523,271-09/960315	or and
	INFORMATION DISCLOSURE STATEMENT	APPLICANT(S) Wannemacher, et al.		9603 24/0
		FILING DATE  March 12, 2000  9/24/61	GROUP Not Assigned 1644	1101
		- POCHAGNTS		

### U.S. PATENT DOCUMENTS

		0.3.1711111			
	LOCKINGENT	DATE NAME	CLASS SU	B-CLASS   FILING DATE	<u>.</u>
EXAMINER'S	Cite DOCUMENT No. NUMBER		CITED	N PTO-892	
INITIAL	AA1 5,453,271	9/26/95   Lemley, et al			
L		TOOCI	TMENTS		

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIAL	Cite No.	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION  Orange Services  No
						IMENTS	

# OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

XAMINE	2,6	Cite		Include Author, Title, Date, Pertinent, etc.
NITIAL	. 3	No.		Blakely & Thrope, Cancer Drug Delivery 3:189-196 (1986).
R		AB.	1	Brugsch, New England Journal of Medicine 262:1039-1040 (1960).
i		AC	1	Brugsch, New England Journal of Measure
				Compton & Gall, Medicine Legal Journal 48:51-62 (1980).
,	\	AD	1	Cookson & Nottingham, Monthly Review Press, New York, NY:259-282
	-	AE	1	Cookson & Nottingham, Monthly Reviews
				(1969).
	-	AF	1	Fodstad, et al, Breast Journal Cancer 34:418-425 (1976).
		'		as D. Akapaylated Ricin BV
		AG	1	Foxwell, et al., "The Preparation Of Deglycosylated Recombination Of Glycosidase-Treated A- And B-Chains: Effects Of Recombination Of Glycosidase-Treated A- And B-Chains: Biochim. Biophys.
				Dealycosylation On Toxicity And Edit
				Acta 923:59-65 (1987).
	1_		1 1	Ghetie & Vitetta, "Recent Developments In Immunotoxin Therapy" Cancer
		AH	$\frac{1}{2}$	Drug Delivery 2:191-198 (1994).
				Ghetie & Vitetta, Curr. Opin. Immunol. 6:707-714 (1994).
	1	AI	1	TO STORY TO THE ST
EXAMI				DATE CONSIDERED 8/5/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO 1449  INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 0207-0004	APPLICATION NO. <del>09/523,271</del> 09/960315
<u>ini onimerio. Casassas da casas a cas</u>	APPLICANT(S) Wannemacher, et al.	
	FILING DATE  March 12, 2000  9/24/01	GROUP Not Assigned 1644

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS CONT.

EXAMINER'S	Cite		Include Author, Title, Date, Pertinent, etc.
INITIAL B	No.	2	Golde, et al., <u>Infect. Immun</u> . 65:882-889 (1997).
	AK	2	Hewetson, et al., "A Formalized Toxoid For Proection Of Mice From Inhaled Ricin" Vaccine Res. 4:179-187 (1995).
	AL	2	Lamb, et al, Eur. J. Biochem. 148:265-270 (1985).
	AM	2	Lemley & Wright, "Mice Are Actively Immunized After Passive Monoclonal Antibody Prophylaxis And Ricin Toxin Challenge"  Immunology 76:511-513 (1992).
	AN .	2	Lindstrom, et al., "An In Vitro Model For Toxin-Mediated Vascular Leak Syndrome: Ricin Toxin A Chain Increases The Permeability Of Human Endothelial Cell Monolayers" <u>Blood</u> 90:2323-2334 (1997).
	AO	2	Lord, et al., <u>FASEB J</u> . 8:201-208 (1984).
	AP	2	Lord, et al., "Ricin Cytotoxicity, Biosynthesis And Use In Immunoconjugates" <u>Prog. Medical Chemical</u> 24:1-28 (1987).
	AQ	2	O'Hare, et al. "Expression Of Ricnin A Chain In Eschericia Coli" FEBS Lett. 216:8-73 (1987).
	AR	2	Roberts, et al., J. Biol. Chem. 15682-15686 (1985)
	AS	2	Soler-Rodriguez, "The Toxicity Of Chemically Deglycosylated Ricin A-Chin In Mice" <u>J. Immunopharmacol</u> 14:281-291 (1992).
	AT	2	Soler-Rodriguez, et al., "Ricin A-Chain And Ricin A-Chain Immunotoxins Rapidly Damage Human Endothelial Cells: Implications For Vascual Leak Syndrome" Exp. Cell. Res. 206:227-234 (1993).
EXAMINER	2.6	2	MAGE DATE CONSIDERED 8/5/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Page 3 of 3

the state of the s		1 uge 3 01 5
FORM PTO 1449  INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 0207-0004	APPLICATION NO. -09/523,271 -09/960315
<u>un ommass</u>	APPLICANT(S) Wannemacher, et al.	
	FILING DATE March 12, 2000	GROUP Not Assigned
	9/24/01	1644

#### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS CONT.

EXAMINER'S INITIAL	Cite No.		Include Author, Title, Date, Pertinent, etc.
PV	AU	3	Thompson, et al., <u>Bact. Res</u> . 11:115-145 (1947).
	AV	3	Thorpe, et al., <u>Eur. J. Biochem</u> . 147:197-206 (1985).
	AW	3	Underwood, et al., <u>Immunology</u> 85:256-261 (1995).
	AY	3	Van Heiningen, F. Ed., In Molecular Action of Toxins and Viruses, Amsterdam: Elsevier Biomedical Press: 51-105 (1982).
	AX	3	Vitetta, et al, "Immunotoxins: Magic Bullets Or Misguided Missiles" <u>Trends Pharmacol. Science</u> 14:148-154 (1993).
	AZ	3	Wawrzynczak, et al., "Comparative Biochemical, Cytotoxic And Pharmacokinetic Properties Of Immunotoxins Made With Native Ricin A Chain, Ricin A <sub>1</sub> Chain And Recombination Ricin A Chain" Int. J. Cancer 47:130-135 (1991).
	ВА	3	Wood, et al, "Preproabrin: Genomic Cloning, Characterization And The Pexpression Of The A-Chain In Escherichia Coli" Eur. J. Biochem. 198:723-732 (1991).
. (	ВВ	3 .	Zajtchuk, R. and R.F. Bellamy Eds., <u>Textbook of Military Medicine</u> , Office of the Surgeon General, Department of the Army, USA: 631-642 (1997).
ENAMINER	2.4		DATE CONSIDERED 8/5/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Applicant.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**EXAMINER**